Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: J Neurosci Res. 2011 Jul 25;89(11):1812–1821. doi: 10.1002/jnr.22712

Fig 2. Effects of CBL in the markers of neurodegeneration 3 and 6 months after therapeutical interruption in APP tg mice.

Fig 2

Immunohistochemical analysis was performed to evaluate the effect of CBL treatment interruption on neurodegeneration in APP tg mice. (a) Levels of the synaptic marker, synaptophysin, in the neocortex of saline-treated non tg and saline or CBL-treated APP tg mice at TPT 0m, TPT 3m and TPT 6m. (b) Levels of synaptophysin, in the hippocampus of saline-treated non tg and saline or CBL-treated APP tg mice at TPT 0m, TPT 3m and TPT 6m. (c) Levels of the neuronal marker, NeuN, in the neocortex of saline-treated non tg and saline or CBL-treated APP tg mice at TPT 0m, TPT 3m and TPT6m. (d) Levels of NeuN, in the hippocampus of saline-treated non tg and saline or CBL-treated APP tg mice at TPT 0m, TPT 3m and TPT 6m. (e) Levels of the astroglial marker, GFAP, in the neocortex of saline-treated non tg and saline or CBL-treated APP tg mice at TPT 0m, TPT 3m and TPT 6m. (f) Levels of GFAP, in the hippocampus of saline-treated non tg and saline or CBL-treated APP tg mice at TPT 0m, TPT 3m and TPT 6m. Error bars represent mean ± SEM. (*)Indicates p<0.05, when comparing APP tg mice with saline-treated non tg mice assessed by one-way ANOVA with post-hoc Dunnett’s and (#) indicates p<0.05 when comparing CBL-treated APP tg mice with saline-treated APP tg mice assessed by one-way ANOVA with post-hoc Dunnett’s.